[ad_1]
Health advisers in the United States reported on Wednesday that need to collect more data on cases of patients who developed clots after receiving the vaccine, before deciding on the next steps for the Johnson & Johnson inoculant.
The group of medical experts convened by the Centers for Disease Control and Prevention of the United States (CDC) had planned to recommend further restrictions on the use of this vaccine after a meeting broadcast live, but instead, they asked for more information, extending the break in their administration.
According to US media, experts have told the government they need more evidence to decide whether a handful of any unusual blood clots were or were not related to the injection and, if so, how high the potential risk is.
On Tuesday, authorities suspended administration of the vaccine due to six cases of thrombosis among the nearly 7 million doses that were administered in the United States.
Clots under investigation are very rare. They’ve happened in strange places, in veins that drain blood from the brain, and in people with abnormally low levels of clot-forming platelets.
The authorities have indicated that Be vigilant, but remember that reports of blood clots which could be related to the J&J vaccine are very rare.
“It’s less than one in a million,” said Dr. Anthony Fauci., the country’s infectious disease expert. As he considered, this is an excess of caution.
Johnson & Johnson’s management hiatus comes after European regulators said these clots were a rare but possible risk with the AstraZeneca vaccine., an injection made in a similar fashion but not yet approved for use in the United States.
In addition, a committee expert said after the meeting that the link between thrombosis in vaccinees against covid-19 with Johnson & Johnson (J&J) and AstraZeneca sera is not clear.
“It is not clear whether the blood clots seen after people receive the AstraZeneca and Johnson & Johnson vaccines are the same,” said Beth Bell.
One of the options is that in the vote that takes place after collecting the necessary information green light to issue a recommendation urging that the suspension of the J&J vaccine continue or that it only apply to certain age groups
Concerns about clots could undermine public confidence in a vaccine that many hoped would help some of the hardest-to-reach populations, in poor countries or in places like homeless shelters in the United States.
Vaccination is slower in Europe, where many countries are scrambling to obtain supplies. J&J delayed some of its European deliveries as part of the clot assessment, but Poland, for example, said it would use the batch it already had in its possession. European medical regulators plan to publish their own assessment of the J&J clot problem next week.
With AP information
KEEP READING:
[ad_2]
Source link